AMRYT PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amryt Pharma Plc – AMYT

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Amryt Pharma Plc (NasdaqGS: AMYT) to
Chiesi Farmaceutici S.p.A. Under the terms of the proposed transaction, shareholders of Amryt will receive $14.50 in cash plus a Contingent Value Right of up to $2.50 (payable if certain milestones
related to Amryt’s product Filsuvez are achieved) for each American Depositary Share (ADS) of Amryt that they own. KSF is seeking to determine whether this consideration and the process that led to
it are adequate, or whether the consideration undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or
call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit

The Amryt Pharma Stock currently trades with a raise of +0,48 % to 14,58USD on the Nasdaq stock

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.